一般演題２１

[O21-3] 中等症から重症の潰瘍性大腸炎患者に対するグセルクマブの有効性と安全性：QUASAR第3相導入試験

*久松 理一¹、 Laurent Peyrin-Biroulet²、Jessica R. Allegretti³、Brian G. Feagan⁴、Brian Bressler⁵、Gary R. Lichtenstein⁶、Kuan-Hsiang G. Huang⁷、Matthew Germinaro⁷、Nicole Shipitofsky⁷、Lingjing Jiang⁷、Hongyan Zhang⁷、Julián Panés⁸、Axel Dignass⁹、Bruce E. Sands¹⁰、David T. Rubin¹¹ (1. 杏林大学医学部消化器内科学、2. Nancy University Hospital, Université de Lorraine, Nancy, France、3. Brigham and Women’s Hospital Crohn’s and Colitis Center, Boston, MA, USA、4. Alimentiv Inc, London, ON, Canada、5. University of British Columbia, Vancouver, BC, Canada、6. University of Pennsylvania, Philadelphia, PA, USA、7. Janssen Research & Development, LLC, Spring House, PA, USA、8. Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain、9. Agaplesion Markus Hospital, Frankfurt, Germany、10. Icahn School of Medicine at Mount Sinai, New York City, NY, USA、11. University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL)